

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

Press Note No. 1 (2014 Series)

**Subject: Setting up off National Centre for Research and Development
 in Bulk Drug (NCRDBD) at NIPER, Hyderabad**

The performance of Bulk Drug sector is one of the critical factors that affect the overall efficiency and cost competitiveness of the pharmaceutical sector. There are nearly 2500 bulk drug manufacturing units in India. The estimated turnover of the Bulk Drug Industry in 2012-13 was around US\$12.5Bn. The industry has shown a CAGR of 16.98% in the last 3 year and has a share of about 10% of the global bulk drugs market of about US\$ 110 Billion. However, the import of Bulk Drugs has seen a CAGR of 18% during last three years indicating an increasing level of dependence on international supply for this critical input of pharmaceutical sector. This is further compounded by the fact that more than 60% share in imports of Intermediates for APIs is from a single country. There is urgent need to address these concerns and make the industry cost competitive. In Bulk Drug Industry, the reduced processes and improved technology can help in reducing the cost significantly.

2. Ministry of Chemical and Fertilizer, Department of Pharmaceuticals proposes to take measures to address the concerns of this sector. To meet the objective of reducing the cost through process and technology improvement through Research and Development activities, Ministry of Chemical and Fertilizer, Department of Pharmaceuticals has approved the establishment of National Centre for Research and Development in Bulk Drug (NCRDBD) at NIPER, Hyderabad, at total project cost of Rs. 54.20 crore along with operating cost for five years amounting to Rs. 37.43 crore.

3. This project would fill a crucial existing gap in bulk drug R&D in Pharmaceutical sector and long standing demand of Bulk Drug Manufacturing. The NCRDBD would be an innovative R&D provider in the field of bulk drugs and offer competitive and eco-friendly technologies in specified areas products and processes. This center will also provide centralized research facilities and technologies, analytical facilities and consulting services for process improvement and optimization. It would give special emphasis to the empowerment of MSME sector. The Pharma industry specially the SME sector requires such center since the individual units cannot afford to have their captive R&D facilities.



(Shambhu Kallolikar)

Joint Secretary to the Government of India

Department of Pharmaceuticals File No. 54011/1/2009-NIPER dated 10th July, 2014

Copy forwarded to:

1. Press Information Officer, Press Information Bureau – for giving necessary publicity.
- ✓ 2. Director NIC in the Department of Pharmaceuticals – for uploading the Press Note on DoP's website.